Researchers focus on phosphoinositide 3-kinase pathway in cancer research
The U.S. Army Chemical Materials Agency (CMA) marked the destruction of all VX nerve agent munitions at its destruction sites on Wednesday, Dec. 24, 2008. This milestone occurred with the destruction of the last land mine containing VX at the Anniston Chemical Agent Disposal Facility (ANCDF) in Anniston, Ala. “I commend Anniston and all CMA
Full Post: All VX nerve agent munitions destroyed in U.S.
Researchers are taking a closer look at the phosphoinositide 3-kinase (PI3-kinase) pathway as studies continue to demonstrate that inhibiting this biological route suppresses tumor growth, reports Genetic Engineering & Biotechnology News (GEN ).
The pathway is involved in angiogenesis, cell growth, differentiation, and survival. In addition, it is part of the PI3/AKT/mTOR pathway, which plays a key role in cancer, according to the December issue of GEN (www.genengnews.com).
“The good news about cancer is that a report last month from the National Cancer Institute indicated that there is a decline in both cancer incidence and death rates in the U.S.,” says John Sterling, Editor in Chief of GEN . “But the American Cancer Society estimates that there will still be over half a million cancer deaths in America in 2008 so novel therapies remain critical.”
Exelixis, for example, has developed several potential cancer compounds, two of which (XL147 and XL765) target the PI3-kinase pathway. Company scientists say they are studying the pathway because there are a number of feedback loops that emanate from m-TOR and downstream kinases that circle back to the top of the pathway and turn on AKT, an enzyme that drives tumor survival signals.
Investigators at the University of London are exploring the role of PI3-kinase isoforms in normal physiology and disease. A team led by Dr. Bart Vanhaesebroeck isolated the PI3-kinase genes in various mammals and developed models to better understand gene function.
Also covered in the GEN article is research taking place at Eli Lilly, the Multiple Myeloma Research Foundation, Semafore Pharmaceuticals, Calistoga Pharmaceuticals, and Harvard Medical School.
A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches. In their Nature Medicine report, which is receiving early online release, investigators from Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital (MGH) Cancer Center, and Beth Israel Deaconess
Full Post: Advance in K-Ras-mutated cancer research
Cancer and cell biology experts at the University of Cincinnati (UC) have identified a new tumor suppressor that may help scientists develop more targeted drug therapies to combat lung cancer. The study, led by Jorge Moscat, PhD, appears in the January 2009 issue of Molecular and Cellular Biology . Proto-oncogenes are genes that play a
Full Post: Discovery of new tumor suppressor for lung cancer
University of Texas Medical Branch at Galveston researchers have identified a promising new target in the battle against colorectal cancer - a biochemical pathway critical to the spread of tumors to new locations in the body. If this “survival pathway” can be successfully blocked under clinical conditions, the result would be a much-needed new therapy
Full Post: Discovery of promising new target in the battle against colorectal cancer
Cylene Pharmaceuticals announced today that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman’s disease, or multiple myeloma. The primary endpoints of the oral dose escalating trial are determination of safety, tolerance and PK properties of CX-4945 and to select the
Full Post: Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2
Cancer researchers at the Max Delbr?nter for Molecular Medicine (MDC) Berlin-Buch and the Charité - Universit? Medizin Berlin (Germany) have identified a gene which enables them to predict for the first time with high probability if colon cancer is going to metastasize. Assistant Professor Dr. Ulrike Stein, Professor Peter M. Schlag, and Professor Walter Birchmeier
Full Post: Scientists find gene that is a powerful predictor of colon cancer metastasis